Institutions / Tang Capital Management, LLC / Activity
Activity — Tang Capital Management, LLC
55 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Add | 78462F103 Common stock | $89.75M | +138K +460.00% | 168,000 5.55% of portfolio | high |
| Q1 2026 as of | Exit | Avidity Biosciences, Inc. Common stock | $-64.92M | -900K -100.00% | 0 | high |
| Q1 2026 as of | Add | Corcept Therapeutics Inc Common stock | $54.15M | +1.3M +856.85% | 1,500,000 3.07% of portfolio | high |
| Q1 2026 as of | Add | Capricor Therapeutics, Inc. Common stock | $51.68M | +1.7M +99.99% | 3,399,900 5.25% of portfolio | high |
| Q1 2026 as of | Exit | Vertex Pharmaceuticals Inc / Ma Common stock | $-36.27M | -80K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Insmed Inc Common stock | $32.70M | +200K +333.33% | 260,000 2.16% of portfolio | medium |
| Q1 2026 as of | Trim | Moderna, Inc. Common stock | $-30.12M | -593K -85.57% | 100,000 0.26% of portfolio | medium |
| Q1 2026 as of | Exit | Travere Therapeutics, Inc. Common stock | $-26.75M | -700K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Ventyx Biosciences, Inc. Common stock | $-25.41M | -2.8M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | NVIDIA Corp Common stock | $-23.83M | -128K -100.00% | 0 | medium |
| Q1 2026 as of | New | CMPS COMPASS Pathways plc ADR | $22.13M | +4.0M | 4,002,200 1.12% of portfolio | medium |
| Q1 2026 as of | Add | Ani Pharmaceuticals Inc Common stock | $17.38M | +226K +46.96% | 707,500 2.76% of portfolio | medium |
| Q1 2026 as of | Exit | Meta Platforms Inc Common stock | $-15.40M | -23K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | 37733W204 Common stock | $-14.71M | -300K -100.00% | 0 | medium |
| Q1 2026 as of | Add | AUPH Aurinia Pharmaceuticals Inc. Common Stock | $13.34M | +900K +7.94% | 12,229,500 9.20% of portfolio | medium |
| Q1 2026 as of | Exit | Vaxcyte, Inc. Common stock | $-12.69M | -275K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | ERAS Erasca, Inc. Common Stock | $-11.33M | -700K -77.78% | 200,000 0.16% of portfolio | medium |
| Q1 2026 as of | Exit | Harmony Biosciences Holdings Inc Common stock | $-10.86M | -290K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Bristol Myers Squibb Co Common stock | $-10.79M | -200K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Teladoc Health, Inc. Common stock | $-9.80M | -1.4M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | 268158201 Common stock | $-8.56M | -556K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Verastem, Inc. Common stock | $-8.26M | -1.1M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | ACADIA Pharmaceuticals Inc Common stock | $-8.01M | -300K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Sarepta Therapeutics, Inc. Common stock | $-7.52M | -349K -100.00% | 0 | medium |
| Q1 2026 as of | New | Janux Therapeutics, Inc. Common stock | $6.95M | +500K | 500,000 0.35% of portfolio | medium |
| Q1 2026 as of | Exit | G8807B106 Common stock | $-6.57M | -351K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Biocryst Pharmaceuticals Inc Common stock | $-6.24M | -800K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Regeneron Pharmaceuticals, Inc. Common stock | $-6.17M | -8K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Crescent Biopharma, Inc. Common stock | $5.28M | +288K +32.97% | 1,160,000 1.08% of portfolio | medium |
| Q1 2026 as of | Exit | IBRX ImmunityBio, Inc. Common Stock | $-4.62M | -2.3M -100.00% | 0 | low |
| Q1 2026 as of | Trim | Altimmune Inc Common stock | $-4.51M | -1.5M -68.75% | 666,022 0.10% of portfolio | low |
| Q1 2026 as of | Trim | 36315X101 Common stock | $-4.06M | -135K -3.45% | 3,785,991 5.77% of portfolio | low |
| Q1 2026 as of | Trim | LENZ Therapeutics, Inc. Common stock | $-3.79M | -414K -47.86% | 451,114 0.21% of portfolio | low |
| Q1 2026 as of | New | Agios Pharmaceuticals, Inc. Common stock | $3.38M | +100K | 100,000 0.17% of portfolio | low |
| Q1 2026 as of | Trim | Evolus, Inc. Common stock | $-3.13M | -763K -61.22% | 483,021 0.10% of portfolio | low |
| Q1 2026 as of | Add | Precigen, Inc. Common stock | $3.10M | +800K +14.24% | 6,417,500 1.26% of portfolio | low |
| Q1 2026 as of | Trim | NUVB Nuvation Bio Inc. Common Stock | $-3.04M | -708K -18.35% | 3,149,557 0.69% of portfolio | low |
| Q1 2026 as of | Trim | Abeona Therapeutics Inc. Common stock | $-2.69M | -600K -60.00% | 400,000 0.09% of portfolio | low |
| Q1 2026 as of | Exit | Nuvalent, Inc. Common stock | $-2.20M | -22K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Alexandria Real Estate Equities Inc Common stock | $-1.96M | -40K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Sutro Biopharma, Inc. Common stock | $-1.62M | -140K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Biohaven Ltd. Common stock | $-1.58M | -140K -100.00% | 0 | low |
| Q1 2026 as of | Trim | Coherus Oncology, Inc. Common stock | $-1.42M | -838K -30.75% | 1,886,748 0.16% of portfolio | low |
| Q1 2026 as of | Exit | Revolution Medicines, Inc. Common stock | $-1.25M | -16K -100.00% | 0 | low |
| Q1 2026 as of | Trim | DERM Journey Medical Corp Common Stock | $-1.15M | -245K -13.19% | 1,610,000 0.38% of portfolio | low |
| Q1 2026 as of | Trim | NMRA Neumora Therapeutics, Inc. Common Stock | $-1.03M | -527K -54.52% | 439,878 0.04% of portfolio | low |
| Q1 2026 as of | Exit | Zymeworks Inc. Common stock | $-911.8K | -35K -100.00% | 0 | low |
| Q1 2026 as of | Trim | PMVP PMV Pharmaceuticals, Inc. Common Stock | $-861.7K | -695K -14.07% | 4,245,085 0.27% of portfolio | low |
| Q1 2026 as of | Add | IMCR Immunocore Holdings Plc-Adr ADR | $628.0K | +21K +0.79% | 2,649,368 4.06% of portfolio | low |
| Q1 2026 as of | New | LXRX Lexicon Pharmaceuticals, Inc. Common Stock | $623.5K | +400K | 399,700 0.03% of portfolio | low |